^
Association details:
| Biomarker: | STAT3 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | Promacta (eltrombopag) (Thrombopoietin receptor agonist) + cyclosporin A microemulsion (Calcineurin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/19/2021
Excerpt:
Myelodysplastic Syndromes: Patients generally ≤60 y and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones. IST includes equine ATG ± cyclosporin A ± eltrombopag.
